The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-09-20

AUTHORS

Emanuela Palmerini, Marco Colangeli, Cristina Nanni, Stefano Fanti, Emanuela Marchesi, Anna Paioli, Piero Picci, Silvia Cambioli, Davide Donati, Luca Cevolani, Massimiliano De Paolis, Marco Gambarotti, Stefano Ferrari

ABSTRACT

PurposeThe histological response to neoadjuvant chemotherapy is an important prognostic factor in patients with osteosarcoma (OS) and Ewing sarcoma (EWS). The aim of this study was to assess baseline primary tumour FDG uptake on PET/CT, and serum values of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH), to establish whether these factors are correlated with tumour necrosis and prognosis.MethodsPatients treated between 2009 and 2014 for localized EWS and OS, who underwent FDG PET/CT as part of their staging work-up, were included. The relationships between primary tumour SUVmax at baseline (SUV1), SUVmax after induction chemotherapy (SUV2), metabolic response calculated as [(SUV1 − SUV2)/SUV1)] × 100, LDH and ALP and tumour response/survival were analysed. A good response (GR) was defined as tumour necrosis >90 % in patients with OS, and grade II-III Picci necrosis (persitence of microscopic foci only or no viable tumor) in patients with Ewing sarcoma.ResultsThe study included 77 patients, 45 with EWS and 32 with OS. A good histological response was achieved in 53 % of EWS patients, and 41 % of OS patients. The 3-year event-free survival (EFS) was 57 % in EWS patients and 48 % OS patients. The median SUV1 was 5.6 (range 0 – 17) in EWS patients and 7.9 (range 0 – 24) in OS patients (p = 0.006). In EWS patients the GR rate was 30 % in those with a high SUV1 (≥6) and 72 % in those with a lower SUV1 (p = 0.0004), and in OS patients the GR rate was 29 % in those with SUV1 ≥6 and 64 % in those with a lower SUV1 (p = 0.05). In the univariate analysis the 3-year EFS was significantly better in patients with a low ALP level (59 %) than in those with a high ALP level (22 %, p = 0.02) and in patients with a low LDH level (62 %) than in those with a high LDH level (37 %, p = 0.004). In EWS patients the 3-year EFS was 37 % in those with a high SUV1 and 75 % in those with a low SUV1 (p = 0.004), and in OS patients the 3-year EFS was 32 % in those with a high SUV1 and 66 % in those with a low SUV1 (p = 0.1). Histology, age and gender were not associated with survival. In the multivariate analysis, SUV1 was the only independent pretreatment prognostic factor to retain statistical significance (p = 0.017). SUV2 was assessed in 25 EWS patients: the median SUV2 was 1.9 (range 1 – 8). The GR rate was 20 % in patients with a high SUV2, and 67 % in those with a low SUV2 (p = 0.02). A good metabolic response (SUV reduction of ≥55 %) was associated with a 3-year EFS of 80 % and a poor metabolic response with a 3-year EFS of 20 % (p = 0.05). In the OS patients the median SUV2 was 2.7 (range 0 – 4.5). Neither SUV2 nor the metabolic response was associated with outcome in OS patients.ConclusionFDG PET/CT is a useful and noninvasive tool for identifying patients who are more likely to be resistant to chemotherapy. If this finding is confirmed in a larger series, SUV1, SUV2 and metabolic response could be proposed as factors for stratifying EWS patients to identify those with high-grade localized bone EWS who would benefit from risk-adapted induction chemotherapy. More... »

PAGES

215-223

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00259-016-3509-z

DOI

http://dx.doi.org/10.1007/s00259-016-3509-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018885026

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27645694


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemoradiotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorodeoxyglucose F18", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Italy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron Emission Tomography Computed Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prevalence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sarcoma, Ewing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palmerini", 
        "givenName": "Emanuela", 
        "id": "sg:person.01210215667.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Colangeli", 
        "givenName": "Marco", 
        "id": "sg:person.01003041354.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003041354.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.412311.4", 
          "name": [
            "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nanni", 
        "givenName": "Cristina", 
        "id": "sg:person.01275354033.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275354033.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.412311.4", 
          "name": [
            "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fanti", 
        "givenName": "Stefano", 
        "id": "sg:person.0715016706.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715016706.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marchesi", 
        "givenName": "Emanuela", 
        "id": "sg:person.0720354404.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720354404.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paioli", 
        "givenName": "Anna", 
        "id": "sg:person.01235471460.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235471460.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Laboratory, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Research Laboratory, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Picci", 
        "givenName": "Piero", 
        "id": "sg:person.0753274552.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753274552.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.412311.4", 
          "name": [
            "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cambioli", 
        "givenName": "Silvia", 
        "id": "sg:person.01057244143.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057244143.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Donati", 
        "givenName": "Davide", 
        "id": "sg:person.01202643430.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202643430.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cevolani", 
        "givenName": "Luca", 
        "id": "sg:person.01007135564.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007135564.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Paolis", 
        "givenName": "Massimiliano", 
        "id": "sg:person.0705203110.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705203110.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiology, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Surgical Pathology, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
            "Radiology, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gambarotti", 
        "givenName": "Marco", 
        "id": "sg:person.01334463454.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334463454.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferrari", 
        "givenName": "Stefano", 
        "id": "sg:person.013005321532.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013005321532.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s002590000340", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019676038", 
          "https://doi.org/10.1007/s002590000340"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-014-2924-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049588764", 
          "https://doi.org/10.1007/s10549-014-2924-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7819-12-26", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032219566", 
          "https://doi.org/10.1186/1477-7819-12-26"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-015-3200-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013429857", 
          "https://doi.org/10.1007/s00259-015-3200-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-013-2344-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010594474", 
          "https://doi.org/10.1007/s00259-013-2344-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12094-015-1351-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009995151", 
          "https://doi.org/10.1007/s12094-015-1351-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-09-20", 
    "datePublishedReg": "2016-09-20", 
    "description": "PurposeThe histological response to neoadjuvant chemotherapy is an important prognostic factor in patients with osteosarcoma (OS) and Ewing sarcoma (EWS). The aim of this study was to assess baseline primary tumour FDG uptake on PET/CT, and serum values of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH), to establish whether these factors are correlated with tumour necrosis and prognosis.MethodsPatients treated between 2009 and 2014 for localized EWS and OS, who underwent FDG PET/CT as part of their staging work-up, were included. The relationships between primary tumour SUVmax at baseline (SUV1), SUVmax after induction chemotherapy (SUV2), metabolic response calculated as [(SUV1\u2009\u2212\u2009SUV2)/SUV1)]\u2009\u00d7\u2009100, LDH and ALP and tumour response/survival were analysed. A good response (GR) was defined as tumour necrosis >90\u00a0% in patients with OS, and grade II-III Picci necrosis (persitence of microscopic foci only or no viable tumor) in patients with Ewing sarcoma.ResultsThe study included 77 patients, 45 with EWS and 32 with OS. A good histological response was achieved in 53\u00a0% of EWS patients, and 41\u00a0% of OS patients. The 3-year event-free survival (EFS) was 57\u00a0% in EWS patients and 48\u00a0% OS patients. The median SUV1 was 5.6 (range 0\u2009\u2013\u200917) in EWS patients and 7.9 (range 0\u2009\u2013\u200924) in OS patients (p\u2009=\u20090.006). In EWS patients the GR rate was 30\u00a0% in those with a high SUV1 (\u22656) and 72\u00a0% in those with a lower SUV1 (p\u2009=\u20090.0004), and in OS patients the GR rate was 29\u00a0% in those with SUV1 \u22656 and 64\u00a0% in those with a lower SUV1 (p\u2009=\u20090.05). In the univariate analysis the 3-year EFS was significantly better in patients with a low ALP level (59\u00a0%) than in those with a high ALP level (22\u00a0%, p\u2009=\u20090.02) and in patients with a low LDH level (62\u00a0%) than in those with a high LDH level (37\u00a0%, p\u2009=\u20090.004). In EWS patients the 3-year EFS was 37\u00a0% in those with a high SUV1 and 75\u00a0% in those with a low SUV1 (p\u2009=\u20090.004), and in OS patients the 3-year EFS was 32\u00a0% in those with a high SUV1 and 66\u00a0% in those with a low SUV1 (p\u2009=\u20090.1). Histology, age and gender were not associated with survival. In the multivariate analysis, SUV1 was the only independent pretreatment prognostic factor to retain statistical significance (p\u2009=\u20090.017). SUV2 was assessed in 25 EWS patients: the median SUV2 was 1.9 (range 1\u2009\u2013\u20098). The GR rate was 20\u00a0% in patients with a high SUV2, and 67\u00a0% in those with a low SUV2 (p\u2009=\u20090.02). A good metabolic response (SUV reduction of \u226555\u00a0%) was associated with a 3-year EFS of 80\u00a0% and a poor metabolic response with a 3-year EFS of 20\u00a0% (p\u2009=\u20090.05). In the OS patients the median SUV2 was 2.7 (range 0\u2009\u2013\u20094.5). Neither SUV2 nor the metabolic response was associated with outcome in OS patients.ConclusionFDG PET/CT is a useful and noninvasive tool for identifying patients who are more likely to be resistant to chemotherapy. If this finding is confirmed in a larger series, SUV1, SUV2 and metabolic response could be proposed as factors for stratifying EWS patients to identify those with high-grade localized bone EWS who would benefit from risk-adapted induction chemotherapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00259-016-3509-z", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "event-free survival", 
      "PET/CT", 
      "FDG PET/CT", 
      "OS patients", 
      "Ewing's sarcoma", 
      "EWS patients", 
      "neoadjuvant chemotherapy", 
      "induction chemotherapy", 
      "prognostic factors", 
      "LDH levels", 
      "metabolic response", 
      "tumor necrosis", 
      "histological response", 
      "ALP levels", 
      "ConclusionFDG PET/CT", 
      "primary tumor FDG uptake", 
      "good histological response", 
      "poor metabolic response", 
      "bone Ewing's sarcoma", 
      "primary tumor SUVmax", 
      "high LDH levels", 
      "pretreatment prognostic factors", 
      "important prognostic factor", 
      "tumor FDG uptake", 
      "response/survival", 
      "alkaline phosphatase", 
      "good metabolic response", 
      "low ALP levels", 
      "good response", 
      "lower LDH levels", 
      "higher ALP levels", 
      "tumor SUVmax", 
      "bone sarcomas", 
      "FDG uptake", 
      "grade II", 
      "univariate analysis", 
      "ResultsThe study", 
      "serum values", 
      "chemotherapy", 
      "patients", 
      "SUV1", 
      "large series", 
      "multivariate analysis", 
      "osteosarcoma", 
      "SUV2", 
      "noninvasive tool", 
      "sarcoma", 
      "necrosis", 
      "CT", 
      "statistical significance", 
      "SUVmax", 
      "survival", 
      "response", 
      "MethodsPatients", 
      "prognosis", 
      "factors", 
      "levels", 
      "histology", 
      "baseline", 
      "age", 
      "outcomes", 
      "rate", 
      "study", 
      "gender", 
      "aim", 
      "findings", 
      "LDH", 
      "uptake", 
      "phosphatase", 
      "dehydrogenase", 
      "GR rate", 
      "significance", 
      "role", 
      "analysis", 
      "relationship", 
      "series", 
      "part", 
      "tool", 
      "values"
    ], 
    "name": "The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas", 
    "pagination": "215-223", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018885026"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00259-016-3509-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27645694"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00259-016-3509-z", 
      "https://app.dimensions.ai/details/publication/pub.1018885026"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_712.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00259-016-3509-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3509-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3509-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3509-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3509-z'


 

This table displays all metadata directly associated to this object as RDF triples.

350 TRIPLES      21 PREDICATES      133 URIs      118 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00259-016-3509-z schema:about N08be1051e88c44a98d956a6af7cf5b2e
2 N1515d77151414306b6a9c80a90ca1714
3 N202273da31ee491f9a36ee4006a6a2a7
4 N2fda6b0e0cfa45bf8000551e2dfbe681
5 N309196dd34184784a837f139404f78a4
6 N3762fd3f573e43d8bca282ae3b31ddfb
7 N392dcd5dbc0249f2a2c348bd988054d6
8 N3dfab6336a0e408bb8e8e8333da3afea
9 N5c102b083c544d869f837cf177308f06
10 N6b8060f584564b1a936e72faba0e61b5
11 N79c8a04a9483494188d98bad5feb887b
12 N88e99b8f4d2440e4a3d874a3020c0e5e
13 N9314565493b2484cb113910ad761d261
14 Na28ebc6fafe44de5be33abe83ae2f09b
15 Na2dd3c3a3538476aa20411c786dc4bed
16 Na9b7de3f1e864e58b9232667e8c37d43
17 Nc43ea9f0336c4033953eb69b0e4d89a1
18 Ncae402a667f044f787314c3cae428ef1
19 Ne271db2b2cde461c81f5edd6103d5cd5
20 Ned3cde226f664624b881679a602207e2
21 Nf40681af94ae48b999a3a80f4005837f
22 Nf80598d8e5ac491f9a4a9c3cebb7ff55
23 anzsrc-for:11
24 anzsrc-for:1103
25 anzsrc-for:1112
26 schema:author Na40321615574402eb465a4669ee6810d
27 schema:citation sg:pub.10.1007/s00259-013-2344-8
28 sg:pub.10.1007/s00259-015-3200-9
29 sg:pub.10.1007/s002590000340
30 sg:pub.10.1007/s10549-014-2924-8
31 sg:pub.10.1007/s12094-015-1351-6
32 sg:pub.10.1186/1477-7819-12-26
33 schema:datePublished 2016-09-20
34 schema:datePublishedReg 2016-09-20
35 schema:description PurposeThe histological response to neoadjuvant chemotherapy is an important prognostic factor in patients with osteosarcoma (OS) and Ewing sarcoma (EWS). The aim of this study was to assess baseline primary tumour FDG uptake on PET/CT, and serum values of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH), to establish whether these factors are correlated with tumour necrosis and prognosis.MethodsPatients treated between 2009 and 2014 for localized EWS and OS, who underwent FDG PET/CT as part of their staging work-up, were included. The relationships between primary tumour SUVmax at baseline (SUV1), SUVmax after induction chemotherapy (SUV2), metabolic response calculated as [(SUV1 − SUV2)/SUV1)] × 100, LDH and ALP and tumour response/survival were analysed. A good response (GR) was defined as tumour necrosis >90 % in patients with OS, and grade II-III Picci necrosis (persitence of microscopic foci only or no viable tumor) in patients with Ewing sarcoma.ResultsThe study included 77 patients, 45 with EWS and 32 with OS. A good histological response was achieved in 53 % of EWS patients, and 41 % of OS patients. The 3-year event-free survival (EFS) was 57 % in EWS patients and 48 % OS patients. The median SUV1 was 5.6 (range 0 – 17) in EWS patients and 7.9 (range 0 – 24) in OS patients (p = 0.006). In EWS patients the GR rate was 30 % in those with a high SUV1 (≥6) and 72 % in those with a lower SUV1 (p = 0.0004), and in OS patients the GR rate was 29 % in those with SUV1 ≥6 and 64 % in those with a lower SUV1 (p = 0.05). In the univariate analysis the 3-year EFS was significantly better in patients with a low ALP level (59 %) than in those with a high ALP level (22 %, p = 0.02) and in patients with a low LDH level (62 %) than in those with a high LDH level (37 %, p = 0.004). In EWS patients the 3-year EFS was 37 % in those with a high SUV1 and 75 % in those with a low SUV1 (p = 0.004), and in OS patients the 3-year EFS was 32 % in those with a high SUV1 and 66 % in those with a low SUV1 (p = 0.1). Histology, age and gender were not associated with survival. In the multivariate analysis, SUV1 was the only independent pretreatment prognostic factor to retain statistical significance (p = 0.017). SUV2 was assessed in 25 EWS patients: the median SUV2 was 1.9 (range 1 – 8). The GR rate was 20 % in patients with a high SUV2, and 67 % in those with a low SUV2 (p = 0.02). A good metabolic response (SUV reduction of ≥55 %) was associated with a 3-year EFS of 80 % and a poor metabolic response with a 3-year EFS of 20 % (p = 0.05). In the OS patients the median SUV2 was 2.7 (range 0 – 4.5). Neither SUV2 nor the metabolic response was associated with outcome in OS patients.ConclusionFDG PET/CT is a useful and noninvasive tool for identifying patients who are more likely to be resistant to chemotherapy. If this finding is confirmed in a larger series, SUV1, SUV2 and metabolic response could be proposed as factors for stratifying EWS patients to identify those with high-grade localized bone EWS who would benefit from risk-adapted induction chemotherapy.
36 schema:genre article
37 schema:isAccessibleForFree true
38 schema:isPartOf N290ee2364a4d484598de07f37603a37b
39 N49663f697f9e4a51adba0270810c6de9
40 sg:journal.1297401
41 schema:keywords ALP levels
42 CT
43 ConclusionFDG PET/CT
44 EWS patients
45 Ewing's sarcoma
46 FDG PET/CT
47 FDG uptake
48 GR rate
49 LDH
50 LDH levels
51 MethodsPatients
52 OS patients
53 PET/CT
54 ResultsThe study
55 SUV1
56 SUV2
57 SUVmax
58 age
59 aim
60 alkaline phosphatase
61 analysis
62 baseline
63 bone Ewing's sarcoma
64 bone sarcomas
65 chemotherapy
66 dehydrogenase
67 event-free survival
68 factors
69 findings
70 gender
71 good histological response
72 good metabolic response
73 good response
74 grade II
75 high LDH levels
76 higher ALP levels
77 histological response
78 histology
79 important prognostic factor
80 induction chemotherapy
81 large series
82 levels
83 low ALP levels
84 lower LDH levels
85 metabolic response
86 multivariate analysis
87 necrosis
88 neoadjuvant chemotherapy
89 noninvasive tool
90 osteosarcoma
91 outcomes
92 part
93 patients
94 phosphatase
95 poor metabolic response
96 pretreatment prognostic factors
97 primary tumor FDG uptake
98 primary tumor SUVmax
99 prognosis
100 prognostic factors
101 rate
102 relationship
103 response
104 response/survival
105 role
106 sarcoma
107 series
108 serum values
109 significance
110 statistical significance
111 study
112 survival
113 tool
114 tumor FDG uptake
115 tumor SUVmax
116 tumor necrosis
117 univariate analysis
118 uptake
119 values
120 schema:name The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas
121 schema:pagination 215-223
122 schema:productId N42df724e80454fa2b59595fe878a364e
123 N56dd8059f8f44fee849ba0b24c24fc1f
124 Ne5bc905ceec1482ca07e19cd74b191e7
125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018885026
126 https://doi.org/10.1007/s00259-016-3509-z
127 schema:sdDatePublished 2022-11-24T21:00
128 schema:sdLicense https://scigraph.springernature.com/explorer/license/
129 schema:sdPublisher N642648e9f86b4c99bd63ae2308cf10ef
130 schema:url https://doi.org/10.1007/s00259-016-3509-z
131 sgo:license sg:explorer/license/
132 sgo:sdDataset articles
133 rdf:type schema:ScholarlyArticle
134 N040a953a93364d45be12fd3dde393dc5 rdf:first sg:person.01202643430.41
135 rdf:rest N981841a563ff4ebcaf33c93b21bca03c
136 N08be1051e88c44a98d956a6af7cf5b2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Bone Neoplasms
138 rdf:type schema:DefinedTerm
139 N1515d77151414306b6a9c80a90ca1714 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Sarcoma, Ewing
141 rdf:type schema:DefinedTerm
142 N176b7c16f9514fc2b188d70941a4939b rdf:first sg:person.0715016706.32
143 rdf:rest N56f7806d74814de8ba344e6e0aefcd77
144 N202273da31ee491f9a36ee4006a6a2a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Child, Preschool
146 rdf:type schema:DefinedTerm
147 N290ee2364a4d484598de07f37603a37b schema:issueNumber 2
148 rdf:type schema:PublicationIssue
149 N2fda6b0e0cfa45bf8000551e2dfbe681 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Chemoradiotherapy, Adjuvant
151 rdf:type schema:DefinedTerm
152 N309196dd34184784a837f139404f78a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Prevalence
154 rdf:type schema:DefinedTerm
155 N3762fd3f573e43d8bca282ae3b31ddfb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Fluorodeoxyglucose F18
157 rdf:type schema:DefinedTerm
158 N392dcd5dbc0249f2a2c348bd988054d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Radiopharmaceuticals
160 rdf:type schema:DefinedTerm
161 N3dfab6336a0e408bb8e8e8333da3afea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Female
163 rdf:type schema:DefinedTerm
164 N42df724e80454fa2b59595fe878a364e schema:name pubmed_id
165 schema:value 27645694
166 rdf:type schema:PropertyValue
167 N49663f697f9e4a51adba0270810c6de9 schema:volumeNumber 44
168 rdf:type schema:PublicationVolume
169 N56dd8059f8f44fee849ba0b24c24fc1f schema:name dimensions_id
170 schema:value pub.1018885026
171 rdf:type schema:PropertyValue
172 N56f7806d74814de8ba344e6e0aefcd77 rdf:first sg:person.0720354404.13
173 rdf:rest N902e4a4b56ea4d78a4c7d98713455ac2
174 N5c102b083c544d869f837cf177308f06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Positron Emission Tomography Computed Tomography
176 rdf:type schema:DefinedTerm
177 N5e9ce3f6e6f74157a259e78606b3aad6 rdf:first sg:person.0705203110.24
178 rdf:rest N87b146930ffb4bd28d926569979d0a98
179 N642648e9f86b4c99bd63ae2308cf10ef schema:name Springer Nature - SN SciGraph project
180 rdf:type schema:Organization
181 N6b8060f584564b1a936e72faba0e61b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Male
183 rdf:type schema:DefinedTerm
184 N753a1ea5c8c9462bbd61aeb198411397 rdf:first sg:person.01003041354.87
185 rdf:rest Naad71d53279a44d3acf5087f99c93c47
186 N79c8a04a9483494188d98bad5feb887b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Child
188 rdf:type schema:DefinedTerm
189 N7a65060ffa954b71937bf6864310e24b rdf:first sg:person.01057244143.41
190 rdf:rest N040a953a93364d45be12fd3dde393dc5
191 N87b146930ffb4bd28d926569979d0a98 rdf:first sg:person.01334463454.00
192 rdf:rest Nea56bd5132e040508f26290ac30f7d58
193 N88e99b8f4d2440e4a3d874a3020c0e5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Prognosis
195 rdf:type schema:DefinedTerm
196 N902e4a4b56ea4d78a4c7d98713455ac2 rdf:first sg:person.01235471460.73
197 rdf:rest Nba6d4effdfe34e638c4c2b8e2d35497e
198 N9314565493b2484cb113910ad761d261 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Risk Assessment
200 rdf:type schema:DefinedTerm
201 N981841a563ff4ebcaf33c93b21bca03c rdf:first sg:person.01007135564.48
202 rdf:rest N5e9ce3f6e6f74157a259e78606b3aad6
203 Na28ebc6fafe44de5be33abe83ae2f09b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Italy
205 rdf:type schema:DefinedTerm
206 Na2dd3c3a3538476aa20411c786dc4bed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Adult
208 rdf:type schema:DefinedTerm
209 Na40321615574402eb465a4669ee6810d rdf:first sg:person.01210215667.35
210 rdf:rest N753a1ea5c8c9462bbd61aeb198411397
211 Na9b7de3f1e864e58b9232667e8c37d43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Survival Rate
213 rdf:type schema:DefinedTerm
214 Naad71d53279a44d3acf5087f99c93c47 rdf:first sg:person.01275354033.99
215 rdf:rest N176b7c16f9514fc2b188d70941a4939b
216 Nba6d4effdfe34e638c4c2b8e2d35497e rdf:first sg:person.0753274552.44
217 rdf:rest N7a65060ffa954b71937bf6864310e24b
218 Nc43ea9f0336c4033953eb69b0e4d89a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Risk Factors
220 rdf:type schema:DefinedTerm
221 Ncae402a667f044f787314c3cae428ef1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Adolescent
223 rdf:type schema:DefinedTerm
224 Ne271db2b2cde461c81f5edd6103d5cd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
225 schema:name Young Adult
226 rdf:type schema:DefinedTerm
227 Ne5bc905ceec1482ca07e19cd74b191e7 schema:name doi
228 schema:value 10.1007/s00259-016-3509-z
229 rdf:type schema:PropertyValue
230 Nea56bd5132e040508f26290ac30f7d58 rdf:first sg:person.013005321532.44
231 rdf:rest rdf:nil
232 Ned3cde226f664624b881679a602207e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
233 schema:name Humans
234 rdf:type schema:DefinedTerm
235 Nf40681af94ae48b999a3a80f4005837f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
236 schema:name Neoadjuvant Therapy
237 rdf:type schema:DefinedTerm
238 Nf80598d8e5ac491f9a4a9c3cebb7ff55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
239 schema:name Treatment Outcome
240 rdf:type schema:DefinedTerm
241 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
242 schema:name Medical and Health Sciences
243 rdf:type schema:DefinedTerm
244 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
245 schema:name Clinical Sciences
246 rdf:type schema:DefinedTerm
247 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
248 schema:name Oncology and Carcinogenesis
249 rdf:type schema:DefinedTerm
250 sg:journal.1297401 schema:issn 1619-7070
251 1619-7089
252 schema:name European Journal of Nuclear Medicine and Molecular Imaging
253 schema:publisher Springer Nature
254 rdf:type schema:Periodical
255 sg:person.01003041354.87 schema:affiliation grid-institutes:grid.419038.7
256 schema:familyName Colangeli
257 schema:givenName Marco
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003041354.87
259 rdf:type schema:Person
260 sg:person.01007135564.48 schema:affiliation grid-institutes:grid.419038.7
261 schema:familyName Cevolani
262 schema:givenName Luca
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007135564.48
264 rdf:type schema:Person
265 sg:person.01057244143.41 schema:affiliation grid-institutes:grid.412311.4
266 schema:familyName Cambioli
267 schema:givenName Silvia
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057244143.41
269 rdf:type schema:Person
270 sg:person.01202643430.41 schema:affiliation grid-institutes:grid.419038.7
271 schema:familyName Donati
272 schema:givenName Davide
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202643430.41
274 rdf:type schema:Person
275 sg:person.01210215667.35 schema:affiliation grid-institutes:grid.419038.7
276 schema:familyName Palmerini
277 schema:givenName Emanuela
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35
279 rdf:type schema:Person
280 sg:person.01235471460.73 schema:affiliation grid-institutes:grid.419038.7
281 schema:familyName Paioli
282 schema:givenName Anna
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235471460.73
284 rdf:type schema:Person
285 sg:person.01275354033.99 schema:affiliation grid-institutes:grid.412311.4
286 schema:familyName Nanni
287 schema:givenName Cristina
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275354033.99
289 rdf:type schema:Person
290 sg:person.013005321532.44 schema:affiliation grid-institutes:grid.419038.7
291 schema:familyName Ferrari
292 schema:givenName Stefano
293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013005321532.44
294 rdf:type schema:Person
295 sg:person.01334463454.00 schema:affiliation grid-institutes:grid.419038.7
296 schema:familyName Gambarotti
297 schema:givenName Marco
298 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334463454.00
299 rdf:type schema:Person
300 sg:person.0705203110.24 schema:affiliation grid-institutes:grid.419038.7
301 schema:familyName De Paolis
302 schema:givenName Massimiliano
303 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705203110.24
304 rdf:type schema:Person
305 sg:person.0715016706.32 schema:affiliation grid-institutes:grid.412311.4
306 schema:familyName Fanti
307 schema:givenName Stefano
308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715016706.32
309 rdf:type schema:Person
310 sg:person.0720354404.13 schema:affiliation grid-institutes:grid.419038.7
311 schema:familyName Marchesi
312 schema:givenName Emanuela
313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720354404.13
314 rdf:type schema:Person
315 sg:person.0753274552.44 schema:affiliation grid-institutes:grid.419038.7
316 schema:familyName Picci
317 schema:givenName Piero
318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753274552.44
319 rdf:type schema:Person
320 sg:pub.10.1007/s00259-013-2344-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010594474
321 https://doi.org/10.1007/s00259-013-2344-8
322 rdf:type schema:CreativeWork
323 sg:pub.10.1007/s00259-015-3200-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013429857
324 https://doi.org/10.1007/s00259-015-3200-9
325 rdf:type schema:CreativeWork
326 sg:pub.10.1007/s002590000340 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019676038
327 https://doi.org/10.1007/s002590000340
328 rdf:type schema:CreativeWork
329 sg:pub.10.1007/s10549-014-2924-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049588764
330 https://doi.org/10.1007/s10549-014-2924-8
331 rdf:type schema:CreativeWork
332 sg:pub.10.1007/s12094-015-1351-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009995151
333 https://doi.org/10.1007/s12094-015-1351-6
334 rdf:type schema:CreativeWork
335 sg:pub.10.1186/1477-7819-12-26 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032219566
336 https://doi.org/10.1186/1477-7819-12-26
337 rdf:type schema:CreativeWork
338 grid-institutes:grid.412311.4 schema:alternateName Nuclear Medicine, Sant’ Orsola Hospital, Bologna, Italy
339 schema:name Nuclear Medicine, Sant’ Orsola Hospital, Bologna, Italy
340 rdf:type schema:Organization
341 grid-institutes:grid.419038.7 schema:alternateName Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
342 Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
343 Radiology, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
344 Research Laboratory, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
345 schema:name Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
346 Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
347 Radiology, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
348 Research Laboratory, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
349 Surgical Pathology, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
350 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...